Safety Study of RMJH-111b to Treat Essential Hypertension

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 10, 2016

Primary Completion Date

July 7, 2016

Study Completion Date

July 7, 2016

Conditions

Essential Hypertension

Interventions

DRUG

Magnesium citrate, tribasic anhydrous soft gelatin capsule

110 mg elemental magnesium/capsule

DRUG

Placebo soft gelatin capsule

0 mg elemental magnesium/capsule

Trial Locations (1)

Orange County Research Center, Tustin

All Listed Sponsors

lead

RMJ Holdings, LLC

INDUSTRY

NCT02822222 - Safety Study of RMJH-111b to Treat Essential Hypertension | Biotech Hunter | Biotech Hunter